The high-dose, alternate-week intravitreal ganciclovir injections for cytomegalovirus retinitis in acquired immune deficiency syndrome patients on highly active antiretroviral therapy.

dc.contributor.authorYutthitham, Kanokwanen_US
dc.contributor.authorRuamviboonsuk, Paisanen_US
dc.date.accessioned2009-05-27T20:49:58Z
dc.date.available2009-05-27T20:49:58Z
dc.date.issued2005-11-10en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractOBJECTIVES: To evaluate the efficacy, and complications of the high-dose, alternate-week, intravitreal ganciclovir injection for cytomegaloviral retinitis (CMVR) in acquired immune deficiency syndrome (AIDS) patients on highly active antiretroviral therapy (HAART). DESIGN: Retrospective case series. PARTICIPANTS: AIDS patients with CMVR and on HAART MATERIAL AND METHOD: The high-dose, 4 mg/0.1 ml, ganciclovir was injected intravitreally to the enrolled patients on an alternate-week basis. The patients were monitored clinically until the retinitis was inactive, then the injections were withdrawn. The injections were re-initiated if relapse occurred. MAIN OUTCOME MEASURES: The number of eyes achieved inactive retinitis and corresponded to the number of injections, number of relapses and corresponded duration, visual acuity during the injection, and complications of the injection. RESULTS: Inactive lesions were found in 42/51 eyes (82.40%), the corresponding mean number of injections was 5.4 (1-18) per eye. There was no relapse and the corresponded duration of follow-up was 5.1 months (1-16). The final visual outcomes were improved or stable in 26 eyes (50.9%). These visual outcomes were statistically related to initial visual acuity (p = 0.022) but not statistically related to the number of injections (p = 0.929). Complications were found in 7/51 eyes (13.7%). They were vitreous haze, immune recovery uveitis, rhegmatogenous retinal detachment, and infectious endophthalmitis. CONCLUSION: The high-dose, alternate-week, intravitreal injection of ganciclovir may be an alternative for the treatment of CMVR in AIDS patients who are on HAART However, the induction course is longer than the weekly regimen and close monitoring of patients is essential.en_US
dc.description.affiliationDepartment of Ophthalmology, Rajavithi Hospital, Bangkok 10400, Thailand.en_US
dc.identifier.citationYutthitham K, Ruamviboonsuk P. The high-dose, alternate-week intravitreal ganciclovir injections for cytomegalovirus retinitis in acquired immune deficiency syndrome patients on highly active antiretroviral therapy. Journal of the Medical Association of Thailand. 2005 Nov; 88 Suppl 9(): S63-8en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/43716
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAIDS-Related Opportunistic Infections --diagnosisen_US
dc.subject.meshAdulten_US
dc.subject.meshAntiretroviral Therapy, Highly Active --methodsen_US
dc.subject.meshCytomegalovirus Retinitis --diagnosisen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshGanciclovir --administration & dosageen_US
dc.subject.meshHumansen_US
dc.subject.meshInjections, Intralesionalen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshRisk Assessmenten_US
dc.subject.meshSeverity of Illness Indexen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVisual Acuityen_US
dc.subject.meshVitreous Body --drug effectsen_US
dc.titleThe high-dose, alternate-week intravitreal ganciclovir injections for cytomegalovirus retinitis in acquired immune deficiency syndrome patients on highly active antiretroviral therapy.en_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description: